Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.60 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 3/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | NPM1 | P06748 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15933046 | 0.93 | ALK (0.59) | ALKAGXTMAP4K1HTR6RPS6KA3 | |
| SCHEMBL17404654 | 0.88 | ALK (0.69) | ALKMAP4K1RPS6KA3FYN | |
| SCHEMBL15933060 | 0.87 | ALK (0.55) | ALKLCKKDREGFR | |
| SCHEMBL15932988 | 0.86 | ALK (0.62) | ALKMAP4K1RPS6KA3LCKKDR | |
| SCHEMBL17404663 | 0.85 | ALK (0.59) | ALKMAP4K1RPS6KA3LCKKDR | |
| SCHEMBL17404662 | 0.85 | ALK (0.59) | ALKMAP4K1RPS6KA3LCKKDR | |
| SCHEMBL15933047 | 0.85 | ALK (0.59) | ALKMAP4K1RPS6KA3LCKKDR | |
| SCHEMBL15933045 | 0.82 | ALK (0.64) | ALKMAP4K1RPS6KA3FYNINSR | |
| SCHEMBL17404661 | 0.80 | ALK (0.77) | ALKKHK | |
| SCHEMBL15933034 | 0.79 | ALK (0.84) | ALKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | ALK 853/4885AGXT 3827/4885MAP4K1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.